Study guide
5.7 CLIA, Laboratory-Developed Tests & FDA Oversight
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
5.7 CLIA, Laboratory-Developed Tests & FDA Oversight
Key Takeaways Explain This Topic AI
CLIA regulates laboratory operations — personnel, quality control, proficiency testing, and validation — and results from a non-CLIA-certified laboratory may not be used for clinical decision-making.
CLIA governs analytic performance; it does not evaluate whether a test is clinically valid or clinically useful for a given indication.
Most genetic tests are laboratory-developed tests designed, validated, and performed within a single laboratory rather than FDA-cleared or approved kits.
Research results must be confirmed in a CLIA-certified laboratory before being used to guide clinical management, which is why a research finding triggers clinical confirmatory testing.
Direct-to-consumer raw data files are not clinically validated and carry high false-positive rates for individual variants, so they require confirmatory clinical testing before any management decision.
Last updated: August 2026
5.7 CLIA, Laboratory-Developed Tests & FDA Oversight
Quick Answer: CLIA certifies laboratory operations — personnel qualifications, quality control, validation, and proficiency testing — and a result used for clinical decision-making must come from a CLIA-certified laboratory. CLIA does not assess clinical validity or utility . Most genetic tests are laboratory-developed tests (LDTs) rather than FDA-cleared kits. Research results and DTC raw data require CLIA-certified confirmation before they drive management.
Subdomain 5C carries 11 scored items on legal and regulatory requirements. Alongside non-discrimination, privacy, documentation, research standards, and patient access, candidates are expected to know the regulatory scaffolding under the reports they interpret — and to recognize the classic vignette in which a result cannot yet be acted on.
CLIA: what it actually regulates
The Clinical Laboratory Improvement Amendments (CLIA) are federal requirements administered by CMS that apply to any laboratory testing human specimens for the purpose of diagnosis, prevention, or treatment. Genetic testing sits in the high-complexity category, which carries the most demanding requirements.
CLIA requirement What it means in a genetics laboratory
Personnel standards Defined qualifications for the laboratory director, technical supervisor, and testing personnel; the director signs out reports and holds regulatory responsibility
Analytic validation Before clinical use, the laboratory must establish accuracy, precision, analytic sensitivity and specificity, reportable range, and reference intervals for each assay
Quality control and quality assurance Ongoing controls, documented corrective action, and periodic review
Proficiency testing Periodic blinded external challenge samples for regulated analytes, with graded performance
- Specimen and record retention Defined retention periods for specimens, reports, and quality records
- Inspection Biennial survey by CMS or a CMS-approved accrediting organization
CAP accreditation (College of American Pathologists) is the most common deemed-status route: a laboratory accredited by CAP satisfies CLIA through CAP's more detailed molecular checklists and proficiency programs. ISO 15189 accreditation appears in some settings, particularly internationally.
The distinction the exam actually tests
CLIA answers "can this laboratory reliably detect what it says it detects?" — analytic validity. It does not answer:
Clinical validity — does the variant this laboratory reliably detects actually predict the disease?
Clinical utility — does knowing the result improve outcomes?
So a CLIA-certified laboratory can produce a technically flawless report on a gene-disease relationship with limited or disputed evidence. Assessing that evidence is the counselor's job, using resources such as ClinGen gene-disease validity classifications — not something CLIA certification settles.
Laboratory-developed tests and FDA oversight
Most clinical genetic tests are laboratory-developed tests : assays designed, validated, and performed within a single laboratory rather than manufactured and distributed as kits.
Category Regulatory route Genetics examples
LDT Historically overseen through CLIA rather than premarket FDA review Most hereditary cancer panels, exome and genome sequencing, most carrier screens
FDA-cleared or approved in vitro diagnostic 510(k) clearance or premarket approval Selected companion diagnostics and a limited number of consumer genetic health risk reports
Companion diagnostic FDA-approved, tied to a specific therapeutic Tests required to determine eligibility for a targeted therapy
FDA has asserted authority over LDTs at various points and the scope of that oversight has been repeatedly contested and litigated. The exam-safe framing is that LDT oversight is a live and shifting regulatory question , that the historical default has been CLIA-based oversight without premarket FDA review, and that a specific test's regulatory status should be verified rather than assumed. Do not memorize a rule that may have changed; know the two frameworks and the difference between them.
- The confirmation rules that generate exam items
- Research results
A finding generated in a research laboratory that is not CLIA-certified may not be used to guide clinical management. When a research study identifies a variant a participant wishes to act on, the pathway is confirmatory testing in a CLIA-certified clinical laboratory , with clinical consent and counseling. This is why research consent documents specify whether results will be returned at all, and why "the study told me I have a BRCA mutation" is the start of a clinical workup rather than a diagnosis.
Direct-to-consumer results and raw data
Product type Clinical standing
DTC health risk reports on a limited variant set Report only the specific variants tested; a "negative" excludes almost nothing, since most pathogenic variants in a gene are not on the array
DTC raw data files Not clinically validated ; third-party interpretation of these files produces high false-positive rates for individual variants
DTC-initiated tests performed in a CLIA laboratory Analytic quality may be adequate, but interpretation and counseling context still require clinical review
The counseling rule is unchanged in either direction: a DTC "positive" requires confirmation in a clinical laboratory before any management change, and a DTC "negative" does not exclude hereditary risk in someone whose personal or family history meets testing criteria. Both errors — acting on an unconfirmed DTC positive and dismissing a strong pedigree because of a DTC negative — appear as distractors.
Reflex confirmation within clinical testing
Even inside CLIA-certified clinical laboratories, high-throughput sequencing findings are commonly confirmed by an orthogonal method or by high-quality read review before reporting, and results driving irreversible decisions — prenatal diagnosis, risk-reducing surgery, cascade testing — warrant confirmation of the specific variant. A counselor asking "was this confirmed, and by what method?" is asking a Domain 5C question, not being difficult.
The laboratory director's role and the counselor's boundary
Under CLIA, the laboratory director carries regulatory responsibility for test validation, quality systems, and report sign-out. A genetic counselor — unless separately qualified and appointed to that role — interprets the report in the counseling context but does not override, re-issue, or informally reclassify a signed laboratory result. Disagreement with a classification is routed through the laboratory's variant review process, with the supporting clinical or segregation evidence supplied. This is the regulatory basis for the scope-of-practice teaching elsewhere in Domain 5D.
Common traps
Treating CLIA certification as evidence that a test is clinically valid or useful .
Acting on a research result without CLIA-certified confirmation.
Treating a DTC raw data variant call as a clinical result, or a DTC negative as excluding hereditary risk.
Assuming every genetic test is FDA-approved ; most are LDTs.
Reclassifying a laboratory's variant call informally instead of submitting evidence through the laboratory's process.
Confusing CAP accreditation with a separate legal requirement rather than a deemed-status route to CLIA compliance.